230 KB33 KB200520252019Gomišček, GregorSollner Dolenc, MarijaVokič, Ninaštevilka:3letnik:70str. 212-219ISSN:0014-8229COBISSID_HOST:4757105URN:URN:NBN:SI:doc-05VYUTMSslSlovensko farmacevtsko društvoFarmacevtski vestnikChagasova bolezenParazitarne boleznitripanocidne učinkovineTrypanosoma cruziChagasova bolezen in učinkovine za njeno zdravljenje| Chagas disease and drug substances for its treatment|Chagas disease, caused by the Trypanosoma cruzi parasite represents a major burden for public health in Latin America and a potential threat to other countries around the world. The infection is transmitted to a person via an infected triatomine bug and it is in the worst, chronic form often manifested as cardiomypathy with hearth rhythm disorders and cardiac failure, some infected people develop gastrointestinal, neurological or mixed changes, which also require appropriate treatment. Despite the fact that disease was first discovered more than a century ago, only two registered drugs - benznidazole (BNZ) and nifurtimox (NF) - are available for the its treatment today, where BNZ is known as the first choice medication. As nitroimidazole antiparasitic agent, BNZ does not only give unsatisfactory results but also has numerous side effects. The treatment of Chagas disease is more than obviously a major therapeutical challenge. With the aim of discovering more effective medicines, scientists started searching for new targets as well as various modifications of already registered substances. The research is currently focused on three targets - CYP51, cruzipain, and DNA of the parasite, which, in addition to the description of Chagas disease, its prevalence and current treatment, is also presented in this articleChagasova bolezen, ki jo povzroča protozojski parazit Trypanosoma cruzi, predstavlja veliko breme javnega zdravja v Latinski Ameriki in potencialno grožnjo državam po vsem svetu. Okužba, ki se na človeka prenese najpogosteje preko okužene stenice, se v najhujši, kronični obliki izrazi kot kardiomiopatija z motnjami srčnega ritma in pojavom srčne odpovedi, nekateri okuženi pa razvijejo prebavne, nevrološke ali mešane spremembe, ki prav tako zahtevajo ustrezno zdravljenje. Kljub dejstvu, da je bila bolezen prvič odkrita že pred več kot sto leti, sta danes za njeno zdravljenje na voljo le dve registrirani zdravili - benznidazol (BNZ) in nifurtimoks (NF), pri čemer velja BNZ za zdravilo prve izbire. Ta učinkovina je nitroimidazolni antiparazitik, ki poleg tega, da pri zdravljenju ne daje zadovoljivih rezultatov, izkazuje tudi številne neželene učinke. Zdravljenje Chagasove bolezni torej več kot očitno predstavlja velik terapevtski izziv, ki so se ga z namenom odkritja učinkovitejših zdravil lotili tako z iskanjem novih tarč, kot tudi z raznimi modifikacijami že registriranih učinkovin. Raziskave so trenutno osredotočene na tri ciljne tarče - CYP51, kruzipain in DNA parazita, kar poleg opisa Chagasove bolezni, njene razširjenosti in trenutnega načina zdravljenja tudi predstavljamo v tem člankuTEXTznanstveno časopisjejournalsSlovenian National E-content AggregatorNational and University Library of SloveniaSlovensko farmacevtsko društvo